BACKGROUND:Patients were recruited from the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, located within the University of Pittsburgh Medical Center. Idiopathic pulmonary fibrosis results in scarring of the lung and respiratory failure, and has a median survival of 3 to 5 years from the time of diagnosis. The purpose of this study was to determine whether patients with idiopathic pulmonary fibrosis and their care partners could be more optimally managed by a disease-management intervention entitled "Program to Reduce Idiopathic Pulmonary Fibrosis Symptoms and Improve Management," which nurses delivered using the format of a support group. We hypothesized that participation would improve perceptions of health-related quality of life (HRQoL) and decrease symptom burden. METHODS:Subjects were 42 participants randomized to an experimental (10 patient/care partner dyads) or control (11 patient/care partner dyads) group. Experimental group participants attended the 6-week program, and controls received usual care. Before and after the program, all participants completed questionnaires designed to assess symptom burden and HRQoL. Patients and care partners in the intervention group were also interviewed in their home to elicit information on their experience after participating in the Program to Reduce Idiopathic Pulmonary Fibrosis Symptoms and Improve Management. RESULTS: After the intervention, experimental group patients rated their HRQoL less positively (P = .038) and tended to report more anxiety (P = .077) compared with controls. Care partners rated their stress at a lower level (P = .018) compared with controls. Course evaluations were uniformly positive. Post-study qualitative interviews with experimental group participants suggested benefits not exemplified by these scores. Patient participants felt less isolated, were able to put their disease into perspective, and valued participating in research and helping others. CONCLUSION: Further exploration of the impact of disease-management interventions in patients with advanced lung disease and their care partners is needed using both qualitative and quantitative methodology. Disease-management interventions have the potential to positively affect patients with advanced lung disease and their care partners.
RCT Entities:
BACKGROUND:Patients were recruited from the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, located within the University of Pittsburgh Medical Center. Idiopathic pulmonary fibrosis results in scarring of the lung and respiratory failure, and has a median survival of 3 to 5 years from the time of diagnosis. The purpose of this study was to determine whether patients with idiopathic pulmonary fibrosis and their care partners could be more optimally managed by a disease-management intervention entitled "Program to Reduce Idiopathic Pulmonary Fibrosis Symptoms and Improve Management," which nurses delivered using the format of a support group. We hypothesized that participation would improve perceptions of health-related quality of life (HRQoL) and decrease symptom burden. METHODS: Subjects were 42 participants randomized to an experimental (10 patient/care partner dyads) or control (11 patient/care partner dyads) group. Experimental group participants attended the 6-week program, and controls received usual care. Before and after the program, all participants completed questionnaires designed to assess symptom burden and HRQoL. Patients and care partners in the intervention group were also interviewed in their home to elicit information on their experience after participating in the Program to Reduce Idiopathic Pulmonary Fibrosis Symptoms and Improve Management. RESULTS: After the intervention, experimental group patients rated their HRQoL less positively (P = .038) and tended to report more anxiety (P = .077) compared with controls. Care partners rated their stress at a lower level (P = .018) compared with controls. Course evaluations were uniformly positive. Post-study qualitative interviews with experimental group participants suggested benefits not exemplified by these scores. Patientparticipants felt less isolated, were able to put their disease into perspective, and valued participating in research and helping others. CONCLUSION: Further exploration of the impact of disease-management interventions in patients with advanced lung disease and their care partners is needed using both qualitative and quantitative methodology. Disease-management interventions have the potential to positively affect patients with advanced lung disease and their care partners.
Authors: Kathleen O Lindell; Zhan Liang; Leslie A Hoffman; Margaret Q Rosenzweig; Melissa I Saul; Joseph M Pilewski; Kevin F Gibson; Naftali Kaminski Journal: Chest Date: 2015-02 Impact factor: 9.410
Authors: Kathleen Oare Lindell; Dio Kavalieratos; Kevin F Gibson; Laura Tycon; Margaret Rosenzweig Journal: Heart Lung Date: 2016-11-18 Impact factor: 2.210
Authors: Sk Tanzir Mehedi; Kawsar Ahmed; Francis M Bui; Musfikur Rahaman; Imran Hossain; Tareq Mahmud Tonmoy; Rakibul Alam Limon; Sobhy M Ibrahim; Mohammad Ali Moni Journal: Biol Methods Protoc Date: 2022-05-30
Authors: Kathleen Oare Lindell; Sara Jo Klein; Melinda S Veatch; Kevin F Gibson; Daniel J Kass; Mehdi Nouraie; Margaret Q Rosenzweig Journal: Ann Am Thorac Soc Date: 2021-11
Authors: Emma Loveman; Vicky R Copley; Jill L Colquitt; David A Scott; Andy J Clegg; Jeremy Jones; Katherine M A O'Reilly; Sally Singh; Claudia Bausewein; Athol Wells Journal: BMC Pharmacol Toxicol Date: 2014-11-19 Impact factor: 2.483